Why Is UNITED THERAPEUTICS (UTHR) Stock Up Today?

United Therapeutics (UTHR) stock rose 12.55% to $541.89 on the day, driven by a favorable court ruling in a patent dispute with Liquidia. The ruling upheld key claims of United Therapeutics' '327 patent and affirmed Liquidia's infringement. Analysts have described the outcome as a meaningful positive for the company.

What Happened

A federal judge ruled in favor of United Therapeutics by upholding claims 1 and 14 of its '327 patent, which relates to the drug Yutrepia. This decision effectively confirms United Therapeutics' exclusive rights to these claims and establishes that Liquidia has infringed on its intellectual property. The ruling is expected to strengthen United Therapeutics' competitive position in the market. RBC Capital has highlighted the significance of the decision, calling it a positive development for the company. The stock price surged in response, reaching a session high of $541.89.

What The Data Shows

The stock closed at a price within its 52-week range of $409.07 to $609.35. The session saw the stock print a fresh 52-week high on September 30. Over the past 90 days, insiders have sold 68 times, totaling $320.1 million, with no insider purchases recorded. Additionally, the CEO, Martine A. Rothblatt, has sold shares on three separate occasions in late September. The stock has a beta of 0.56, indicating it is less volatile than the broader market.

What To Watch

Investors should monitor the final judgment in the case, which is expected within one week of the ruling. The outcome could influence future litigation strategy and market perception. Additionally, coverage breadth and analyst commentary will be key to watch in the coming days.